Second-Line Treatment for High Cholesterol
Introduction to Second-Line Therapy
- The American College of Cardiology recommends adding ezetimibe 10 mg daily to maximally tolerated statin as the preferred second-line therapy when LDL-C goals are not achieved with statin monotherapy alone 1, 2, 3
Treatment Algorithm Based on Risk Category
- For very high-risk patients with clinical ASCVD and LDL-C ≥70 mg/dL on maximally tolerated statin, the American Heart Association recommends adding ezetimibe 10 mg daily (Class IIa recommendation) 3, 4
- If LDL-C remains elevated after adding ezetimibe, the European Society of Cardiology recommends adding PCSK9 inhibitor (evolocumab or alirocumab) (Class IIa recommendation) 1, 2, 3, 4
Alternative Second-Line Options
- The Mayo Clinic suggests considering bempedoic acid as an alternative or additional agent if available 1, 2
- The American College of Cardiology recommends considering colesevelam as add-on therapy if LDL-C goals are not achieved (Class IIb/C) 3, 4
- The European Atherosclerosis Society recommends considering plant sterols/stanols as adjunctive therapy if LDL-C goals are not achieved (Class 3/B) 1, 2
Special Considerations
- For patients with hypertriglyceridemia and elevated LDL-C, the American Diabetes Association recommends considering fibrates (gemfibrozil 600 mg twice daily or fenofibrate 160 mg daily) as reasonable alternatives only when statins are not appropriate 5
- The American Heart Association recommends icosapent ethyl for high or very high-risk patients with triglycerides 135-499 mg/dL despite statin therapy (Class IIa) 3, 4
Monitoring Requirements
- The American College of Cardiology recommends measuring hepatic aminotransferases before starting drug therapy and monitoring in patients at increased risk of hepatotoxicity 1, 2
- The European Society of Cardiology recommends measuring creatine kinase if musculoskeletal symptoms are reported 1, 2
- The American Diabetes Association recommends monitoring glucose or HbA1c if risk factors for diabetes are present 1, 2